Therapeutic options for patients with pulmonary hypertension and interstitial lung disease
Pulmonary hypertensive diseases have been classified by the World Health Organization (WHO) into five groups based on the pathophysiology and characteristics of each disease state. Several targeted therapeutic agents have been developed that combat the vascular remodeling in WHO Group 1 pulmonary ar...
Saved in:
| Main Authors: | John W. Swisher, Eric Weaver |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-06-01
|
| Series: | Therapeutic Advances in Respiratory Disease |
| Online Access: | https://doi.org/10.1177/17534666251335815 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Treatment of Pulmonary Hypertension in Patients with Connective Tissue Disease and Interstitial Lung Disease
by: Shikha Mittoo, et al.
Published: (2010-01-01) -
Effect of pulmonary rehabilitation program in patients with interstitial lung disease with or without pulmonary hypertension
by: Mona Abd Elsalam Taha El Gazzar, et al.
Published: (2025-05-01) -
Rendu-Osler-Weber Disease with High Pulmonary Hypertension and Interstitial Lung Disease
by: Yu. A. Lutokhina, et al.
Published: (2023-05-01) -
Study Design and Rationale for the PHINDER Study: Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection
by: Tejaswini Kulkarni, et al.
Published: (2025-07-01) -
Systematic evaluation of subgroup analyses of inhaled treprostinil in pulmonary hypertension due to interstitial lung disease.
by: Pablo Martínez-Puig, et al.
Published: (2025-01-01)